Journal Article

Opioid therapy vs. multimodal analgesia in head and neck Cancer (OPTIMAL-HN): study protocol for a randomized clinical trial

Zayed, Sondos, Moulin, Dwight E., Read, Nancy, Lang, Pencilla, Sathya, Jinka, Palma, David A., Mendez, Lucas C., Venkatesan, Varagur, Warner, Andrew

2021

Overview

Background Radiation-induced mucositis (RIM) pain confers substantial morbidity for head and neck cancer (HNC) patients undergoing radiotherapy alone (RT) or chemoradiotherapy (CRT), often reducing treatment compliance. However, no standard currently exists for the treatment of RIM, and high dose opioid therapy, with its associated side effects and increased risk for chronic opioid use, remains the cornerstone of HNC pain management. The goal of this randomized clinical trial is to compare multimodal analgesia using analgesic medications with different mechanisms of action, to the institutional standard of opioid analgesia alone, in order to ascertain the optimal analgesic regimen for the management of RIM pain in HNC patients. Methods In this open-label, single-institution, non-inferiority, randomized clinical trial, sixty-two patients with mucosal head and neck malignancies treated with curative-intent radiation will be randomized in a 1:1 ratio, stratified by RT or CRT, between Arm 1: opioid analgesia alone as per the institutional standard, or Arm 2: multimodal analgesia using Pregabalin, Acetaminophen, and Naproxen, in addition to opioids, if required. The primary endpoint is the average 11-Numeric Rating Scale (11-NRS) score for pain during the last week of radiation treatment. Secondary endpoints include: average weekly opioid use, duration of opioid requirement, average daily 11-NRS score for pain, average weekly opioids dispensed, quality of life, hospitalizations for analgesic medication-induced complications, time to feeding tube insertion, weight loss, toxicity, treatment interruptions, and death within 3 months of completing RT treatment. Patients are eligible once analgesia is required for moderate 4/10 pain. Discussion This study will assess the efficacy and safety of multimodal analgesia and its impact on opioid requirements, clinical outcomes, and quality of life, as a potential new standard treatment for RIM pain in HNC patients undergoing definitive RT or CRT. Trial registration ClinicalTrials.gov Identifier: NCT04221165 . Date of registration: January 9, 2020. Appendix 2 reports the World Health Organization trial registration dataset.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Analgesia / Analgesics / Analgesics, Opioid - therapeutic use / Cancer pain / Cancer palliative care / Cancer therapies / Chemotherapy / Clinical trials / Comparative analysis / Creatinine / Diabetic neuropathy / Drug therapy / Equivalence Trials as Topic / Head & neck cancer / Head and neck Cancer / Head and Neck Neoplasms - complications / Head and Neck Neoplasms - drug therapy / Head and Neck Neoplasms - radiotherapy / Humans / Medicine / Medicine & Public Health / Morbidity / Mucositis / Multimodal analgesia / Narcotics / Nonsteroidal anti-inflammatory drugs / Opioid analgesia / Opioids / Ostomy / Pain / Pain Management / Pain Medicine / Palliative care / Palliative Medicine / Quality of Life / Quality of Life Research / Radiation Mucositis / Radiation therapy / Radiotherapy / Randomized clinical trial / Randomized Controlled Trials as Topic / Study Protocol / Testing